Clarus Therapeutics Holdings, Inc.
(NASDAQ) CRXT
Clarus Therapeutics Holdings, Inc. Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$19.24M
Net Income (TTM)
$58.62M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
CRXT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Clarus Therapeutics Holdings, Inc.
Industry
Pharmaceuticals
Sector
Health CareEmployees
16
CEO
Robert E. Dudley, PhD
Website
clarustherapeutics.comHeadquarters
Northbrook, IL 60062, US
CRXT Financials
Key Financial Metrics (TTM)
Gross Margin
81%
Operating Margin
-3%
Net Income Margin
-4%
Return on Equity
33%
Return on Capital
3%
Return on Assets
-1%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$11.24M
Operating Income
$24.72M
EBITDA
$24.70M
Operating Cash Flow
$43.79M
Capital Expenditure
$25.00K
Free Cash Flow
$43.81M
Cash & ST Invst.
$26.41M
Total Debt
$42.27M
Clarus Therapeutics Holdings, Inc. Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
$4.05M
+45.7%
Gross Profit
$2.89M
+29.9%
Gross Margin
71.36%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
16
N/A
Net Income
$12.71M
+29.8%
EBITDA
$6.69M
-647.7%
Quarterly Fundamentals
Net Cash
$21.33M
+85.8%
Accounts Receivable
$8.71M
+39.7%
Inventory
$16.80M
+72.2%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$40.51M
-21.0%
Return on Assets
-1.09%
N/A
Return on Invested Capital
2.77%
N/A
Free Cash Flow
$17.50M
-9429.0%
Operating Cash Flow
$17.50M
-9429.0%